The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | V | Various | |
2 | V08 | Contrast media | |
3 | V08A | X-ray contrast media, iodinated | |
4 | V08AB | Watersoluble, nephrotropic, low osmolar X-ray contrast media |
Code | Title | |
---|---|---|
V08AB01 | Metrizamide | |
V08AB02 | Iohexol | |
V08AB03 | Ioxaglic acid | |
V08AB04 | Iopamidol | |
V08AB05 | Iopromide | |
V08AB06 | Iotrolan | |
V08AB07 | Ioversol | |
V08AB08 | Iopentol | |
V08AB09 | Iodixanol | |
V08AB10 | Iomeprol | |
V08AB11 | Iobitridol | |
V08AB12 | Ioxilan |
Active Ingredient | Description | |
---|---|---|
Iobitriol |
Iobitriol is a urographic and angiographic water-soluble nonionic contrast agent. |
|
Iodixanol |
|
|
Iohexol |
Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. |
|
Iomeprol |
|
|
Iopamidol |
Iopamidol is contrast medium belonging to the new generation of non-ionic compound whose solubility is due to the presence of hydrophilic substitutes in the molecule. This results in a solution of low osmollity when compared with ionic media. |
|
Iopromide |
The contrast-giving substance in the iopromide formulations is iopromide, a non-ionic water-soluble derivative of triiodinated isophthalic acid in which the firmly bound iodine absorbs the X-rays. Injection of iopromide opacifies those vessels or body cavities in the path of flow of the contrast agent, permitting radio-graphic visualization of the internal structures until significant dilution occurs. |
|
Iotrolan |
|
|
Ioversol |
Ioversol is a non-ionic X-ray contrast medium. Intravascular injection of ioversol opacifies those vessels in the path of the flow of the contrast medium, permitting radiographic visualisation of the internal structures until significant haemodilution occurs. |
|
Ioxaglate |
|
Title | Information Source | Document Type | |
---|---|---|---|
GASTROMIRO Solution for oral or rectal administration | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
IOMERON Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ISOVUE 200/250/300/370 Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
NIOPAM Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
OMNIPAQUE Solution | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
OPTIRAY Solution for injection or infusion | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
ULTRAVIST Solution for injection | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
VISIPAQUE Solution for injection | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
XENETIX Solution for injection | MPI, EU: SmPC |